Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 19:30:1611716.
doi: 10.3389/pore.2024.1611716. eCollection 2024.

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

Zsuzsanna Orosz  1 , Árpád Kovács  2
Affiliations
Review

The role of chemoradiotherapy and immunotherapy in stage III NSCLC

Zsuzsanna Orosz et al. Pathol Oncol Res. .

Abstract

Locally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non-small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in defining the best treatment strategy for each patient. For unresectable stage III NSCLC, definitive concurrent chemoradiotherapy (CCRT) was historically recommended as a treatment with a 5-year survival rate ranging from 20% to 30%. The PACIFIC study conducted in 2017 compared the use of chemoradiotherapy and maintenance therapy with the anti-PD-L1 monoclonal antibody durvalumab to a placebo in patients with locally advanced NSCLC who had not experienced disease progression. The study was prospective, randomized, and phase III. The administration of this medication in patients with locally advanced non-small cell lung cancer (NSCLC) has demonstrated a notable improvement in overall survival. Multiple clinical trials are currently exploring various immune checkpoint inhibition regimens to enhance the treatment efficacy in patients with stage III cancer. Our goal is to offer an up-to-date summary of the planned clinical trials for treatment options, focusing on the significant obstacles and prospects in the post-PACIFIC era.

Keywords: NSCLC; chemoradiotherapy; durvalumab; immunotherapy; locally advanced.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin (2023) 73(1):17–48. 10.3322/caac.21763 - DOI - PubMed
    1. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest (2017) 151(1):193–203. 10.1016/j.chest.2016.10.010 - DOI - PubMed
    1. Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, et al. Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. J Thorac Oncol (2021) 16(6):1030–41. 10.1016/j.jtho.2021.01.1628 - DOI - PubMed
    1. Passiglia F, Leone G, Olmetto E, Delcuratolo MD, Tabbò F, Reale ML, et al. Immune-checkpoint inhibition in stage III unresectable NSCLC: challenges and opportunities in the post-PACIFIC era. Lung Cancer (2021) 157:85–91. 10.1016/j.lungcan.2021.05.009 - DOI - PubMed
    1. Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol (2021) 32(12):1637–42. 10.1016/j.annonc.2021.08.1994 - DOI - PubMed

MeSH terms